SMTL ID : 6tcn.2 (1 other biounit)

Crystal structure of the omalizumab Fab - crystal form II

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 2.30 Å

Oligo State

hetero-1-1-mer

Ligands

1 x EDO: 1,2-ETHANEDIOL(Non-functional Binders)

EDO.1: 1 residues within 4Å: Chain A: S.80 1 PLIP interactions: 1 interactions with chain A Hydrogen bonds: A:S.80

1 x TRS: 2-AMINO-2-HYDROXYMETHYL-PROPANE-1,3-DIOL(Non-functional Binders)

TRS.2: 2 residues within 4Å: Chain A: K.194, R.215 2 PLIP interactions: 2 interactions with chain A Hydrogen bonds: A:R.215, A:R.215

1 x SO4: SULFATE ION(Non-functional Binders)

SO4.3: 4 residues within 4Å: Chain B: R.98, S.100, H.101, Y.102 2 PLIP interactions: 2 interactions with chain B Hydrogen bonds: B:H.101 Salt bridges: B:R.98

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Mitropoulou, A.N. et al., Engineering the Fab fragment of the anti-IgE omalizumab to prevent Fab crystallization and permit IgE-Fc complex crystallization. Acta Crystallogr.,Sect.F (2020)

Release Date

2020-03-18

Peptides

Omalizumab Fab: A
Omalizumab Fab: B

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

B
B

Omalizumab Fab

Omalizumab Fab

Related Entries With Identical Sequence